MacroGenics, Inc.

MGNX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $57.2M $182.8M $101.0M $108.9M $123.5M $181.1M $126.5M $220.1M
Accounts Receivable $13.4M $4.3M $10.4M $56.2M $10.4M $23.1M $12.7M $29.6M
Inventory $7.9M $0 $1.2M $1.5M $4.4M $0 — —
Total Current Assets $219.9M $217.5M $251.3M $222.2M $279.6M $312.6M $239.8M $269.1M
Property, Plant & Equipment $12.6M $18.1M $21.8M $29.6M $37.7M $42.2M $48.2M $56.7M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $256.8M $261.7M $298.4M $280.5M $335.2M $378.7M $312.5M $332.1M
Liabilities
Accounts Payable $4.8M $5.0M $6.4M $4.9M $15.5M $8.0M $4.3M $4.0M
Total Current Liabilities $43.1M $55.5M $56.1M $48.6M $74.6M $50.7M $45.2M $59.9M
Long-Term Debt — — — — — — — —
Total Liabilities $201.3M $145.6M $145.8M $138.5M $95.6M $82.9M $81.9M $89.3M
Stockholders' Equity
Retained Earnings $-1.24B $-1.17B $-1.10B $-1.09B $-973.9M $-771.8M $-642.1M $-490.3M
Total Stockholders' Equity $55.6M $116.1M $152.6M $142.0M $239.6M $295.9M $230.6M $242.9M
← Newer Page 1 of 2 Older →